MedTrace Logo

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

NCT05414162 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-06-15

No results posted yet for this study

Summary

Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma. Known side effects include cytokine release syndrome, which has been described to lead to myocarditis, but larger studies exploring this relationship are currently lacking. In this prospective study, the investigators aim to explore the potential effects of CAR T-cell therapy using cardiac MRI on the heart.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiac MRI

Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Julian Luetkens, MD · University Hospital, Bonn

  • Annkristin Heine, MD · University Hospital, Bonn

  • Tobias Holderried, MD · University Hospital, Bonn

  • Dmitrij Kravchenko, MD · University Hospital, Bonn

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-16
Primary Completion
2024-05-31
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05414162 on ClinicalTrials.gov